The Pfizer-BioNTech vaccine had 93% effectiveness against symptomatic infection two weeks after the second dose, compared with Oxford-AstraZeneca's 71%.
Over time, however, the Pfizer-BioNTech's effectiveness dropped while the Oxford-AstraZeneca's remained largely the same.
...
"Both of these vaccines are still doing very well against Delta."
https://www.bbc.com/news/health-58257863
myimage.jpg (343.64 KB, 下載次數: 0)
myimage.jpg (76.37 KB, 下載次數: 0)